Healthcare
•3762 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3762)
| Company | Market Cap | Price |
|---|---|---|
|
MRSN
Mersana Therapeutics, Inc.
Mersana is an oncology-focused biotechnology company with Emi-Le and XMT-2056 in clinical development.
|
$47.06M |
$9.43
-1.57%
|
|
GNTA
Genenta Science S.p.A.
Genenta's lead program is a gene therapy platform.
|
$46.82M |
$2.58
+0.98%
|
|
SER
Serina Therapeutics, Inc.
Direct proprietary POZ drug delivery platform enabling long-acting, subcutaneous drug release for CNS therapeutics.
|
$46.65M |
$4.63
-7.40%
|
|
SKYE
Skye Bioscience, Inc.
Nimacimab is a monoclonal antibody therapeutic targeting CB1, making Monoclonal Antibody Therapeutics the direct product category.
|
$46.48M |
$1.51
+0.67%
|
|
BDSX
Biodesix, Inc.
Biodesix's Nodify and VeriStrat are blood-based diagnostic tests, i.e., liquid biopsy products.
|
$46.46M |
$6.32
-7.54%
|
|
ALGS
Aligos Therapeutics, Inc.
Aligos develops oral small-molecule therapeutics across its pipeline (HBV CAM-E, THR-β agonist, and pan-coronavirus protease inhibitor).
|
$46.04M |
$7.53
-8.73%
|
|
VNRX
VolitionRx Limited
VolitionRx's Nu.Q platform enables liquid biopsy cancer diagnostics by detecting nucleosome/epigenetic biomarkers in blood.
|
$45.13M |
$0.44
+0.35%
|
|
KZR
Kezar Life Sciences, Inc.
AIH is an immune-mediated liver disease and zetomipzomib is an immunomodulatory small molecule in development by Kezar.
|
$44.78M |
$6.11
-1.61%
|
|
TELO
Telomir Pharmaceuticals, Inc. Common Stock
Telomir-1 is described as an oral small molecule therapeutic candidate, directly matching the 'Oral Small Molecule Therapeutics' tag.
|
$44.64M |
$1.50
+0.33%
|
|
FGEN
FibroGen, Inc.
FibroGen's FG-3246 is an oncology-focused therapeutic program, making Biotech - Oncology a core investment theme.
|
$44.50M |
$11.09
-0.27%
|
|
OKUR
OnKure Therapeutics, Inc.
OKUR operates as a clinical-stage biotech focused on oncology therapies, including mutant-selective PI3Kα inhibitors, directly aligning with Biotech - Oncology.
|
$44.18M |
$3.27
-0.15%
|
|
XLO
Xilio Therapeutics, Inc.
Xilio is a clinical-stage biotechnology company focused on oncology therapies, placing it in Biotech - Oncology.
|
$44.01M |
$0.84
-0.81%
|
|
JUNS
Jupiter Neurosciences, Inc.
Direct product category: orally administered small-molecule therapeutics based on a resveratrol platform (JOTROL).
|
$43.70M |
$1.32
-7.69%
|
|
OTLK
Outlook Therapeutics, Inc.
ONS-5010/LYTENAVA is a regulatory-approved ophthalmic formulation of bevacizumab for intravitreal use.
|
$43.64M |
$1.30
+3.57%
|
|
ATNM
Actinium Pharmaceuticals, Inc.
Actinium directly develops radiopharmaceutical therapies using alpha-emitting isotopes (Ac-225) for oncology (ATNM-400, Actimab-A, Iomab-ACT).
|
$43.05M |
$1.38
-0.36%
|
|
GRCE
Grace Therapeutics, Inc.
The company emphasizes proprietary drug-delivery platforms to reformulate existing compounds, a clear fit for 'Drug Delivery Platforms'.
|
$43.01M |
$3.12
-0.95%
|
|
ATHE
Alterity Therapeutics Limited
ATH434 is a small-molecule oral therapeutic in clinical development (Phase 2) for neurodegenerative disease, identified as Alterity's lead product.
|
$42.88M |
$4.05
-3.80%
|
|
LVTX
LAVA Therapeutics N.V.
LAVA Therapeutics operates in oncology biotech, developing cancer therapies based on its Gammabody platform.
|
$42.87M |
$1.60
-1.54%
|
|
PDSB
PDS Biotechnology Corporation
Company is a oncology-focused biotech developing novel immunotherapies for HPV-related cancers (HPV16+ HNSCC).
|
$42.70M |
$0.93
-0.21%
|
|
NOTV
Inotiv, Inc.
Inotiv operates as a CRO delivering nonclinical drug discovery and development services, aligning with the Contract Research Organizations tag.
|
$42.60M |
$1.24
-7.14%
|
|
ZJYL
Jin Medical International Ltd.
The company designs, manufactures, and sells rehabilitation medical devices and biometrics-oriented equipment.
|
$42.56M |
$0.26
+11.84%
|
|
OTLC
Oncotelic Therapeutics, Inc.
Oncotelic's core oncology program OT-101 and nanoparticle platform place it squarely in oncology-focused biotech.
|
$41.81M |
$0.10
|
|
CALC
CalciMedica, Inc.
CalciMedica's lead candidate Auxora is a CRAC channel inhibitor, i.e., an ion channel modulator.
|
$41.78M |
$2.96
|
|
CPIX
Cumberland Pharmaceuticals Inc.
Caldolor is a non-opioid IV analgesic, aligning CPIX with non-opioid pain management products.
|
$41.29M |
$2.75
-7.86%
|
|
LTRN
Lantern Pharma Inc.
Lantern is a biotech company with a focused oncology pipeline and programs.
|
$41.20M |
$3.80
-0.52%
|
|
CELU
Celularity Inc.
Celularity's core products are allogeneic placental-derived cell therapies produced via the IMPACT platform.
|
$41.19M |
$1.73
-11.54%
|
Showing page 29 of 38 (3762 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
